Cargando…

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

BACKGROUND: Migraine has a severe impact on health-related quality of life (HRQoL) affecting physical, emotional, and social aspects of daily living of an individual. Preventive treatment has been demonstrated to improve HRQoL by reducing the frequency of migraine headache days. METHODS: The study u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ford, Janet H., Foster, Shonda A., Nichols, Russell M., Tockhorn-Heidenreich, Antje, Ye, Wenyu, Jackson, James, Cotton, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338330/ https://www.ncbi.nlm.nih.gov/pubmed/32632891 http://dx.doi.org/10.1186/s41687-020-00221-w

Ejemplares similares

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures
por: Ford, Janet, et al.
Publicado: (2021)

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™
por: Zhao, Hongru, et al.
Publicado: (2023)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
por: Citrome, Leslie, et al.
Publicado: (2021)

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
por: Lombard, Louise, et al.
Publicado: (2020)

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine
por: Seo, Jaein, et al.
Publicado: (2023)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
por: Reuter, Uwe, et al.
Publicado: (2021)

Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study
por: Seo, Jaein, et al.
Publicado: (2021)

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
por: Ailani, Jessica, et al.
Publicado: (2022)

Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
por: Okonkwo, Rose, et al.
Publicado: (2021)

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
por: Ueda, Kaname, et al.
Publicado: (2019)

Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data
por: Hirata, Koichi, et al.
Publicado: (2020)

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme
por: Hirata, Koichi, et al.
Publicado: (2020)

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
por: Ford, Janet H, et al.
Publicado: (2018)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication
por: Lombard, Louise, et al.
Publicado: (2020)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
por: Padovani, Alessandro, et al.
Publicado: (2021)

Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression
por: Shao, Qiujun, et al.
Publicado: (2022)

Rates of Major Cardiovascular Events in Severe Asthma: U.S. Real-World and Clinical Trial–Eligible Populations
por: Dayal, Parul, et al.
Publicado: (2021)

Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study
por: Fonseca, Ana Filipa, et al.
Publicado: (2021)

Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China
por: Zhang, Lei, et al.
Publicado: (2023)

Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia
por: Graham-Clarke, Peita L, et al.
Publicado: (2020)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States
por: Harris, Linda, et al.
Publicado: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
por: Rothrock, JF, et al.
Publicado: (2013)

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
por: Ford, Janet, et al.
Publicado: (2020)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
por: Panopoulou, Aikaterini, et al.
Publicado: (2023)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project
por: Gallacher, John, et al.
Publicado: (2019)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Outcomes of ECLS-SHOCK Eligibility Criteria Applied to a Real-World Cohort
por: von Lewinski, Dirk, et al.
Publicado: (2023)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine
por: Ford, Janet H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g23nrpm9mompatha9f5k1puagn